Published in Mol Cell Biol on July 01, 1999
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A (2001) 3.02
Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One (2008) 2.12
The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle (2008) 2.09
Quantitative proteomic analysis of Myc oncoprotein function. EMBO J (2002) 1.89
Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev (2000) 1.87
Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology (2008) 1.83
Proteomic profiling of Myc-associated proteins. Cell Cycle (2010) 1.80
The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol (2007) 1.75
Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J (2000) 1.69
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.61
Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol Cell Biol (2001) 1.61
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
G1 to S phase cell cycle transition in somatic and embryonic stem cells. J Anat (2008) 1.48
Control of cellular senescence by CPEB. Genes Dev (2006) 1.47
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A (2006) 1.46
The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div (2012) 1.46
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J (2000) 1.42
Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. EMBO J (2005) 1.41
Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell (2003) 1.34
Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol (2000) 1.34
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer (2006) 1.33
Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol (2000) 1.29
Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol (2009) 1.28
Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle (2011) 1.27
Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol Appl Pharmacol (2009) 1.23
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell (2011) 1.22
Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol (2000) 1.21
Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol (2008) 1.20
c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol (2001) 1.19
The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol (2000) 1.18
Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J (2003) 1.17
Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J (2013) 1.17
Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition. Proc Natl Acad Sci U S A (2006) 1.11
Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene (2012) 1.08
Polyamine-modulated c-Myc expression in normal intestinal epithelial cells regulates p21Cip1 transcription through a proximal promoter region. Biochem J (2006) 1.08
Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol (2006) 1.07
c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther (2011) 1.04
Cell-context specific role of the E2F/Rb pathway in development and disease. Glia (2010) 1.04
The cell cycle time of CD8+ T cells responding in vivo is controlled by the type of antigenic stimulus. PLoS One (2010) 1.03
An overview of stress response and hypometabolic strategies in Caenorhabditis elegans: conserved and contrasting signals with the mammalian system. Int J Biol Sci (2010) 1.01
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene (2011) 1.00
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology (2009) 0.99
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol (2014) 0.94
c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br J Cancer (2003) 0.94
MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med (2014) 0.94
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. Oncogene (2011) 0.93
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol (2002) 0.91
Oct4 is required ~E7.5 for proliferation in the primitive streak. PLoS Genet (2013) 0.89
The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. Arch Biochem Biophys (2014) 0.89
Nickel compounds induce apoptosis in human bronchial epithelial Beas-2B cells by activation of c-Myc through ERK pathway. Toxicol Appl Pharmacol (2008) 0.89
Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol (2006) 0.88
Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One (2013) 0.86
Differential gene expression in the pig limbal side population: implications for stem cell cycling, replication, and survival. Invest Ophthalmol Vis Sci (2009) 0.86
Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex. Oncogene (2014) 0.85
Bmal1 is required for beta cell compensatory expansion, survival and metabolic adaptation to diet-induced obesity in mice. Diabetologia (2016) 0.84
A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. PLoS One (2009) 0.83
Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. Nat Commun (2014) 0.83
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget (2014) 0.83
TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle (2013) 0.82
Cell cycle progression in response to oxygen levels. Cell Mol Life Sci (2014) 0.82
Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis (2015) 0.81
c-Myc mediates a hypoxia-induced decrease in acetylated histone H4. Biochimie (2009) 0.81
Monoamine oxidase a expression is vital for embryonic brain development by modulating developmental apoptosis. J Biol Chem (2011) 0.81
1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate (2011) 0.81
p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem (2010) 0.81
GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia (2013) 0.81
Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget. Oncotarget (2015) 0.80
Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters. Cell Cycle (2011) 0.80
Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion. Oncotarget (2015) 0.80
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res (2016) 0.79
Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression. Onco Targets Ther (2013) 0.77
On the traces of XPD: cell cycle matters - untangling the genotype-phenotype relationship of XPD mutations. Cell Div (2010) 0.77
Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G. J Biol Chem (2015) 0.77
Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol (2007) 0.77
Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation. Cancer Sci (2015) 0.77
Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol (2002) 0.75
c-Myc is regulated by HIF-2α in chronic hypoxia and influences sensitivity to 5-FU in colon cancer. Oncotarget (2016) 0.75
Expression level is a key determinant of E2F1-mediated cell fate. Cell Death Differ (2017) 0.75
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat Commun (2017) 0.75
Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells. Elife (2017) 0.75
Catfish rhamnose-binding lectin induces G0/1 cell cycle arrest in Burkitt's lymphoma cells via membrane surface Gb3. Glycoconj J (2016) 0.75
Exploring the metabolic and genetic control of gene expression on a genomic scale. Science (1997) 60.15
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell (1983) 25.46
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 19.76
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell (1983) 17.87
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
Principles of CDK regulation. Nature (1995) 13.09
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (1991) 12.00
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
Cellular oncogenes and retroviruses. Annu Rev Biochem (1983) 10.65
Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol (1997) 9.87
The E2F transcription factor is a cellular target for the RB protein. Cell (1991) 9.62
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Mammalian G1 cyclins. Cell (1993) 9.04
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell (1991) 8.00
Sequence-specific DNA binding by the c-Myc protein. Science (1990) 7.75
Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell (1996) 7.69
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev (1993) 7.41
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev (1993) 7.40
D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol (1994) 7.35
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19
New functional activities for the p21 family of CDK inhibitors. Genes Dev (1997) 6.97
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell (1992) 6.08
Association of human cyclin E with a periodic G1-S phase protein kinase. Science (1992) 5.98
The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev (1992) 5.73
The myc oncogene: its role in transformation and differentiation. Annu Rev Genet (1986) 5.40
Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol (1994) 5.18
Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ (1997) 5.14
The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J (1991) 4.96
Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev (1994) 4.93
D-type cyclins. Trends Biochem Sci (1995) 4.74
Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res (1991) 4.60
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol (1998) 4.54
Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res (1996) 4.48
Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (1991) 4.45
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev (1994) 4.30
Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 4.23
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev (1995) 4.19
Myc and Max proteins possess distinct transcriptional activities. Nature (1992) 4.16
Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell (1993) 4.10
Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev (1992) 3.96
Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A (1995) 3.95
A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex. Cell (1992) 3.64
A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev (1993) 3.60
Use of retroviral vectors for gene transfer and expression. Methods Enzymol (1993) 3.50
Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev (1994) 3.47
Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature (1992) 3.43
Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev (1994) 3.27
Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol (1995) 3.19
The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene (1999) 3.17
c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J (1994) 3.01
Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene (1996) 2.96
Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J (1996) 2.59
The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J (1993) 2.57
Microinjected c-myc as a competence factor. Science (1985) 2.56
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene (1994) 2.55
Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature (1997) 2.51
KIN28 encodes a C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae but lacks cyclin-dependent kinase-activating kinase (CAK) activity. Mol Cell Biol (1995) 2.49
Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A (1995) 2.48
Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci U S A (1992) 2.43
An alternative pathway for gene regulation by Myc. EMBO J (1997) 2.43
Human DNA polymerase alpha gene: sequences controlling expression in cycling and serum-stimulated cells. Mol Cell Biol (1991) 2.42
Negative autoregulation of c-myc transcription. EMBO J (1990) 2.38
Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci U S A (1994) 2.34
Myc target genes. Trends Biochem Sci (1997) 2.34
Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev (1995) 2.33
Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem (1997) 2.32
Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A (1993) 2.31
Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature (1993) 2.28
c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev (1998) 2.27
Introduction to the E2F family: protein structure and gene regulation. Curr Top Microbiol Immunol (1996) 2.24
Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev (1994) 2.08
Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol (1994) 2.08
The Cdk-activating kinase (CAK) from budding yeast. Cell (1996) 2.05
Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol (1997) 2.00
Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem (1986) 2.00
Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol (1996) 1.97
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J (1995) 1.92
Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene (1999) 1.89
Myc represses the growth arrest gene gadd45. Oncogene (1997) 1.86
Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol (1995) 1.84
Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J (1997) 1.81
Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene (1994) 1.73
c-myc protein expression in untransformed fibroblasts. Oncogene (1991) 1.72
Regulation of cell cycle duration by c-myc levels. Oncogene (1989) 1.67
Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene (1995) 1.65
p27Kip1 alters the response of cells to mitogen and is part of a cell-intrinsic timer that arrests the cell cycle and initiates differentiation. Curr Biol (1998) 1.61
Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta (1996) 1.60
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science (2005) 9.57
Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ (1997) 5.14
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science (1997) 4.97
Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A (1998) 4.11
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature (1999) 3.99
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol (2001) 2.36
Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol (2000) 2.27
Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol (2001) 2.27
An inducible mammalian amber suppressor: propagation of a poliovirus mutant. Cell (1987) 2.08
Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex. Proc Natl Acad Sci U S A (1993) 2.02
Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene (1999) 1.89
Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res (1999) 1.86
Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci (2002) 1.74
Fructose bisphosphatase of Escherichia coli: cloning of the structural gene (fbp) and preparation of a chromosomal deletion. J Bacteriol (1984) 1.73
Introduction of UAG, UAA, and UGA nonsense mutations at a specific site in the Escherichia coli chloramphenicol acetyltransferase gene: use in measurement of amber, ochre, and opal suppression in mammalian cells. Mol Cell Biol (1986) 1.60
Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. EMBO J (1995) 1.32
Effects of c-myc expression on cell cycle progression. Mol Cell Biol (1994) 1.30
Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. Exp Cell Res (1999) 1.29
Targeting c-Myc-activated genes with a correlation method: detection of global changes in large gene expression network dynamics. Proc Natl Acad Sci U S A (2005) 1.26
Analysis of biological selections for high-efficiency gene targeting. Mol Cell Biol (1995) 1.20
A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene (1993) 1.20
Fructose bisphosphatase of Saccharomyces cerevisiae. Cloning, disruption and regulation of the FBP1 structural gene. J Mol Biol (1985) 1.20
c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol (2001) 1.19
Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells. Cell Growth Differ (1993) 1.17
A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res (2001) 1.10
Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression. Mol Cell Biol (2000) 1.08
AMP-insensitive fructose bisphosphatase in Escherichia coli and its consequences. Proc Natl Acad Sci U S A (1986) 1.04
Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. Mol Cell Biol (1997) 1.03
A new vector for cloning large eukaryotic DNA segments in Escherichia coli. Biotechnology (N Y) (1990) 1.02
Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene (2010) 1.02
Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol Endocrinol (1998) 0.94
Characterization of IkappaB kinases. IkappaB-alpha is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. J Biol Chem (1996) 0.93
Capsid structure of satellite phage P4 and its P2 helper. J Ultrastruct Res (1982) 0.93
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. Oncogene (2011) 0.93
Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res (1999) 0.93
Overproduction of Rb protein after the G1/S boundary causes G2 arrest. Mol Cell Biol (1993) 0.91
Efficient in situ electroporation of mammalian cells grown on microporous membranes. Nucleic Acids Res (1995) 0.84
Biphasic regulation of the preproendothelin-1 gene by c-myc. Endocrinology (1997) 0.81
Isolation of temperature-sensitive mutations in the c-raf-1 catalytic domain and expression of conditionally active and dominant-defective forms of Raf-1 in cultured mammalian cells. Cell Growth Differ (1998) 0.80
Studies of perinuclear and nuclear translocation of the Raf-1 protein in rodent fibroblasts. Biochim Biophys Acta (1998) 0.75